Teligent, Inc. (NASDAQ:TLGT) Director Carole Ben-Maimon acquired 5,000 shares of the business’s stock in a transaction that occurred on Monday, November 13th. The shares were purchased at an average price of $3.48 per share, with a total value of $17,400.00. Following the completion of the acquisition, the director now owns 2,400 shares of the company’s stock, valued at approximately $8,352. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Teligent, Inc. (TLGT) traded up $0.62 during trading on Monday, reaching $3.74. 2,751,000 shares of the company’s stock traded hands, compared to its average volume of 1,031,454. The company has a debt-to-equity ratio of 1.99, a quick ratio of 3.71 and a current ratio of 4.37. Teligent, Inc. has a 52-week low of $2.82 and a 52-week high of $9.54.

Teligent (NASDAQ:TLGT) last posted its earnings results on Monday, November 6th. The company reported ($0.08) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.01) by ($0.07). The business had revenue of $13.65 million for the quarter, compared to analyst estimates of $19.12 million. Teligent had a negative return on equity of 6.38% and a negative net margin of 16.95%. The company’s quarterly revenue was down 15.5% compared to the same quarter last year. During the same period in the previous year, the company earned $0.01 earnings per share. sell-side analysts predict that Teligent, Inc. will post -0.13 EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: This report was originally reported by American Banking News and is the sole property of of American Banking News. If you are accessing this report on another site, it was stolen and reposted in violation of US and international trademark & copyright law. The legal version of this report can be accessed at https://www.americanbankingnews.com/2017/11/13/teligent-inc-tlgt-director-acquires-17400-00-in-stock.html.

Several brokerages recently issued reports on TLGT. Roth Capital set a $9.00 price objective on Teligent and gave the stock a “buy” rating in a report on Wednesday, August 9th. Zacks Investment Research lowered Teligent from a “hold” rating to a “strong sell” rating in a report on Saturday. Canaccord Genuity lowered Teligent from a “buy” rating to a “hold” rating and cut their price objective for the stock from $9.00 to $5.00 in a report on Tuesday, November 7th. BidaskClub lowered Teligent from a “hold” rating to a “sell” rating in a report on Monday, July 24th. Finally, TheStreet lowered Teligent from a “c-” rating to a “d+” rating in a report on Wednesday, November 1st. Three equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and one has given a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average price target of $7.33.

Institutional investors have recently bought and sold shares of the business. Parkwood LLC acquired a new position in Teligent during the second quarter worth $112,000. UBS Asset Management Americas Inc. acquired a new stake in shares of Teligent in the first quarter valued at about $170,000. Renaissance Technologies LLC acquired a new stake in shares of Teligent in the first quarter valued at about $198,000. American International Group Inc. grew its position in shares of Teligent by 7.1% in the first quarter. American International Group Inc. now owns 25,488 shares of the company’s stock valued at $199,000 after purchasing an additional 1,680 shares during the last quarter. Finally, Voya Investment Management LLC grew its position in shares of Teligent by 16.1% in the second quarter. Voya Investment Management LLC now owns 23,342 shares of the company’s stock valued at $214,000 after purchasing an additional 3,234 shares during the last quarter. 65.85% of the stock is currently owned by hedge funds and other institutional investors.

Teligent Company Profile

Teligent, Inc is a specialty generic pharmaceutical company. Under the Company’s own label, it markets and sells generic injectable pharmaceutical products in the United States and Canada. In the United States it marketed 16 generic topical pharmaceutical products and four branded generic pharmaceutical products, as of December 31, 2016.

Receive News & Ratings for Teligent Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teligent Inc. and related companies with MarketBeat.com's FREE daily email newsletter.